Diazabicyclooctane derivatives useful as matrix metalloproteinase inhibitors

A compound of Formula (I):

• wherein:
• {circle around (A)} is phenyl, C3-C10cycloalkyl ring, C2-C9heterocycloalkyl ring, or a C2-C9heteroaryl ring;
• {circle around (B)} is phenyl, C3-C10cycloalkyl ring, C2-C9heterocycloalkyl ring, or a C2-C9heteroaryl ring;
• X is —C(═O)— or —S(═O)2-;
• Y is a direct bond, —O—, —CH2O—, —OCH2—, —CH2—, —C(═O)NH—, or —N(R5)—;
• wherein if nitrogen is the attachment point on {circle around (B)} for attaching Y then Y cannot be —O—;
• wherein Y, if asymmetrical, is written in the sequence corresponding to {circle around (A)}-Y-{circle around (B)};
• R1 is hydrogen, —C1-C6alkyl, —C1-C6haloalkyl,-C1-C6alkylene-OR6, —C1-C6alkylene-N(R6)2, —C(═O)R7, —C(═O)OR6, —C(═O)N(R6)2, —S(═O)2R7, or —S(═O)2N(R6)2;
• R2 is —C(═O)NH(OH), —CH2N(OH)C(═O)R8, —CH(OH)N(═O), —C(═O)CF3, —CH2NHS(═O)2R8,-CH(NH2)C(═O)OH,-C2-C9heteroaryl, —C(═O)—C2-C9heteroaryl, or —C(═O)NH—C2-C9-heteroaryl;
• each R3 and each R4 are each independently selected from halogen,-C1-C6alkyl,-C1-C6haloalkyl, —OR6, —N(R6)2, —CN, —C(═O)R7, —C(═O)OR6, —C(═O)N(R6)2, —NR6C(═O)R7, —NR6SO2R7, —SO2R7, and —SO2N(R6)2;
• R5 is hydrogen or —C1-C6alkyl;
• each R6 is independently selected from hydrogen,-C1-C6alkyl, —CF3,-C1-C6alkylene-OR9, —C1-C6alkylene-N(R9)2, and —C1-C6alkylene-C2-C9heterocycloalkyl;
• each R7 is independently selected from-C1-C6alkyl,-C1-C6alkylene-OR9,-C1-C6alkylene-N(R9)2, —C2-C9heterocycloalkyl,-C2-C9heteroaryl, —C1-C6alkylene-C2-C9heterocycloalkyl, and —C1-C6alkylene-C2-C9heteroaryl;
• R8 is selected from hydrogen,-C1-C6alkyl, and —N(H)C1-C6alkyl;
• each R9 is independently selected from hydrogen and —C1-C6alkyl;
• each occurrence of C2-C9heterocycloalkyl and C2-C9heteroaryl being optionally substituted with-C1-C6alkyl or CF3;
• n is 0, 1, or 2;
• p is 0, 1, 2, or 3;
• and
• q is 0, 1, 2, or 3;
• or a pharmaceutically acceptable salt or solvate thereof.